Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sa...(uct pipeline crisis and the biotech ...)

Date:12/16/2008

uct pipeline crisis and the biotech industry's capital drought. For further information, please visit Celtic Pharma's website at www.celticpharma.com. "Forward-Looking Statements Certain statements in this press release are not historical facts, including statements that are preceded by, or followed by, or that include words such as "may," "expect," "anticipate," "believe," or "plan," or similar statements, are forward-looking statements that involve risks and uncertainties, including risks relating to the results of the clinical trials for XERECEPT(R) and the ability of Celtic Pharma or Neurobiological Technologies, Inc. (NASDAQ: NTII) ("NTI") to obtain regulatory approval for XERECEPT(R), as well as other risks detailed from time to time in NTI's Securities and Exchange Commission filings. Copies of these filings are available from NTI upon request. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of release. We disclaim, however, any intent to update these forward looking statements."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stro
'/>"/>

SOURCE Neurobiological Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
2. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
3. Neurobiological Technologies Sets Date for First Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
6. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
8. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
9. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
10. Neurobiological Technologies CEO to Retire on December 31, 2008
11. Neurobiological Technologies Reports Third Quarter Financial Results